IV BAL101553: Additional Phase I/IIa data

Data from 39 evaluable patients who failed standard therapy in an open-label, U.K. Phase I/IIa trial showed that the recommended Phase II dose of 30 mg/m 2 IV BAL101553 on days 1, 8 and 15 of a 28-day...